Inhaled antiseptics and inhaled antiviral non-prescription drugs in the prevention of ARVI, in particular COVID-19: an epidemiological study

Infusion & Chemotherapy Pub Date : 2021-12-27 DOI:10.32902/2663-0338-2021-4-5-15

Y. Feshchenko, M. Gumeniuk, М. Lynnyk, O. Dziublyk, M. Kuzhko, О. Tereshkovych, O. Khmel, I. Panashchuk, M.V. Yashchenko, Оleksiy S. Denysov, Т.А. Sprynsian

{"title":"Inhaled antiseptics and inhaled antiviral non-prescription drugs in the prevention of ARVI, in particular COVID-19: an epidemiological study","authors":"Y. Feshchenko, M. Gumeniuk, М. Lynnyk, O. Dziublyk, M. Kuzhko, О. Tereshkovych, O. Khmel, I. Panashchuk, M.V. Yashchenko, Оleksiy S. Denysov, Т.А. Sprynsian","doi":"10.32902/2663-0338-2021-4-5-15","DOIUrl":null,"url":null,"abstract":"BACKGROUND. The article presents the results of a continuous, cross-sectional, non-interventional, multicenter retrospective epidemiological study, which included cases of 3443 participants. Questionnaires and rapid test for antibodies to SARS-CoV-2 were used to collect data. \nOBJECTIVE. To determine the relationship between the systematic use of additional drugs for the prevention of COVID-19, including inhaled antiseptics and inhaled antiviral drugs, separately and in combination with other drugs, and the risk of developing of coronavirus disease (COVID-19). \nRESULTS AND DISCUSSION. 396 participants (11.8 %) took inhaled antiseptics in any period since March 2020, and 410 participants (12.2 %) took inhaled antivirals. A statistically significant protective relationship between episode of COVID-19 when taking inhaled antiseptics and inhaled antiviral drugs (risk ratio 0.901; 95 % confidence interval 0.856-0.948) was determined. \nCONCLUSIONS. The use of inhaled antiseptics and inhaled antiviral drugs as additional methods of prevention of COVID-19 has shown a statistically significant effect not only on reducing the risk of COVID-19, but different combinations of inhaled antiseptics or inhaled antiviral drugs with other drug groups as additional methods of preventing COVID-19 had a statistically significant protective relationship with the episode of the disease, with the severity of COVID-19 and with the need for hospitalization.","PeriodicalId":13681,"journal":{"name":"Infusion & Chemotherapy","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infusion & Chemotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32902/2663-0338-2021-4-5-15","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

BACKGROUND. The article presents the results of a continuous, cross-sectional, non-interventional, multicenter retrospective epidemiological study, which included cases of 3443 participants. Questionnaires and rapid test for antibodies to SARS-CoV-2 were used to collect data. OBJECTIVE. To determine the relationship between the systematic use of additional drugs for the prevention of COVID-19, including inhaled antiseptics and inhaled antiviral drugs, separately and in combination with other drugs, and the risk of developing of coronavirus disease (COVID-19). RESULTS AND DISCUSSION. 396 participants (11.8 %) took inhaled antiseptics in any period since March 2020, and 410 participants (12.2 %) took inhaled antivirals. A statistically significant protective relationship between episode of COVID-19 when taking inhaled antiseptics and inhaled antiviral drugs (risk ratio 0.901; 95 % confidence interval 0.856-0.948) was determined. CONCLUSIONS. The use of inhaled antiseptics and inhaled antiviral drugs as additional methods of prevention of COVID-19 has shown a statistically significant effect not only on reducing the risk of COVID-19, but different combinations of inhaled antiseptics or inhaled antiviral drugs with other drug groups as additional methods of preventing COVID-19 had a statistically significant protective relationship with the episode of the disease, with the severity of COVID-19 and with the need for hospitalization.

查看原文本刊更多论文

吸入消毒剂和吸入抗病毒非处方药预防ARVI，特别是COVID-19:一项流行病学研究

背景。本文介绍了一项连续、横断面、非介入、多中心回顾性流行病学研究的结果，其中包括3443名参与者的病例。采用问卷调查和SARS-CoV-2抗体快速检测方法收集数据。目标。确定系统使用额外的预防COVID-19药物，包括吸入性防腐剂和吸入性抗病毒药物，单独或与其他药物合用，与发生冠状病毒病(COVID-19)的风险之间的关系。结果和讨论。自2020年3月以来的任何时期，396名参与者(11.8%)吸入了防腐剂，410名参与者(12.2%)吸入了抗病毒药物。吸入消毒剂和吸入抗病毒药物时发生COVID-19的保护关系有统计学意义(风险比0.901;95%置信区间0.856 ~ 0.948)。结论。使用吸入性防腐剂和吸入性抗病毒药物作为新冠肺炎的附加预防方法，不仅在降低新冠肺炎风险方面具有统计学意义，而且不同组合使用吸入性防腐剂或吸入性抗病毒药物作为附加预防方法与疾病发作、新冠肺炎严重程度和住院需要具有统计学意义的保护关系。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Infusion & Chemotherapy

自引率

0.00%

发文量